179 related articles for article (PubMed ID: 37860180)
21. Repeat Transurethral Resection for Non-muscle-invasive Bladder Cancer: An Updated Systematic Review and Meta-analysis in the Contemporary Era.
Yanagisawa T; Kawada T; von Deimling M; Bekku K; Laukhtina E; Rajwa P; Chlosta M; Pradere B; D'Andrea D; Moschini M; Karakiewicz PI; Teoh JY; Miki J; Kimura T; Shariat SF
Eur Urol Focus; 2024 Jan; 10(1):41-56. PubMed ID: 37495458
[TBL] [Abstract][Full Text] [Related]
22. Systematic review and meta-analysis of radiation therapy for high-risk non-muscle invasive bladder cancer.
Rodrigues Pessoa R; Mueller AC; Boxley P; Flaig TW; Piper C; Konety B; Yu JB; Gershman B; Kukreja J; Kim SP
Urol Oncol; 2021 Nov; 39(11):786.e1-786.e8. PubMed ID: 33846085
[TBL] [Abstract][Full Text] [Related]
23. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
Zazzara M; Nazaraj A; Scarcia M; Cardo G; Carando R; Ludovico GM
Urol Int; 2023; 107(1):64-71. PubMed ID: 34933307
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Immediate Postoperative Instillation of Chemotherapy for Primary Non-Muscle-Invasive Bladder Cancer in Real-World Clinical Practice.
Murakami K; Hamada A; Teramoto Y; Matsumoto K; Kita Y; Saito R; Yamasaki T; Matsui Y; Inoue T; Ogawa O; Kobayashi T
Clin Genitourin Cancer; 2019 Oct; 17(5):e1003-e1010. PubMed ID: 31402280
[TBL] [Abstract][Full Text] [Related]
25. Impact of sex on outcomes after surgery for non-muscle-invasive and muscle-invasive bladder urothelial carcinoma: a systematic review and meta-analysis.
Mori K; Yanagisawa T; Katayama S; Laukhtina E; Pradere B; Mostafaei H; Quhal F; Rajwa P; Moschini M; Soria F; D'andrea D; Abufaraj M; Albisinni S; Krajewski W; Fukuokaya W; Miki J; Kimura T; Egawa S; Teoh JY; Shariat SF;
World J Urol; 2023 Apr; 41(4):909-919. PubMed ID: 35963957
[TBL] [Abstract][Full Text] [Related]
26. Combination of Intravesical Chemotherapy and Bacillus Calmette-Guerin Versus Bacillus Calmette-Guerin Monotherapy in Intermediate- and High-risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis.
Cui J; Wang W; Chen S; Chen P; Yang Y; Guo Y; Zhu Y; Chen F; Shi B
Medicine (Baltimore); 2016 Jan; 95(3):e2572. PubMed ID: 26817914
[TBL] [Abstract][Full Text] [Related]
27. Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.
Houghton BB; Chalasani V; Hayne D; Grimison P; Brown CS; Patel MI; Davis ID; Stockler MR
BJU Int; 2013 May; 111(6):977-83. PubMed ID: 23253618
[TBL] [Abstract][Full Text] [Related]
28. Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy.
Mayr R; Eckstein M; Wirtz RM; Santiago-Walker A; Baig M; Sundaram R; Carcione JC; Stoehr R; Hartmann A; Bolenz C; Burger M; Otto W; Erben P; Breyer J
Eur Urol; 2022 Jun; 81(6):606-614. PubMed ID: 35351346
[TBL] [Abstract][Full Text] [Related]
29. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results.
Packiam VT; Lamm DL; Barocas DA; Trainer A; Fand B; Davis RL; Clark W; Kroeger M; Dumbadze I; Chamie K; Kader AK; Curran D; Gutheil J; Kuan A; Yeung AW; Steinberg GD
Urol Oncol; 2018 Oct; 36(10):440-447. PubMed ID: 28755959
[TBL] [Abstract][Full Text] [Related]
30. Development of a dynamic risk system for predicting the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer after thulium laser resection of bladder tumor or transurethral resection of bladder tumor followed by intravesical BCG instillation.
Sun JX; An Y; Xu MY; Liu CQ; Xu JZ; Xia QD; Wang SG
Front Oncol; 2023; 13():1133161. PubMed ID: 37476386
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer.
Magalhães JC; Sousa M; Basto R; Fraga T; Gomes I; Fernandes C; Mariano M; Paulo J; Madeira P; Sousa G
Cureus; 2023 Sep; 15(9):e45672. PubMed ID: 37745737
[TBL] [Abstract][Full Text] [Related]
32. Gemcitabine as first-line therapy for high-grade non-muscle invasive bladder cancer: results from a tertiary center in the contemporary BCG-shortage era.
Zeng J; Funk J; Lee BR; Hsu CH; Messing EM; Chipollini J
Transl Androl Urol; 2023 Jun; 12(6):960-966. PubMed ID: 37426602
[TBL] [Abstract][Full Text] [Related]
33. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.
Li R; Sundi D; Zhang J; Kim Y; Sylvester RJ; Spiess PE; Poch MA; Sexton WJ; Black PC; McKiernan JM; Steinberg GD; Kamat AM; Gilbert SM
Eur Urol; 2020 Sep; 78(3):387-399. PubMed ID: 32143924
[TBL] [Abstract][Full Text] [Related]
34. Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non-muscle-invasive Bladder Cancer.
Galesloot TE; Grotenhuis AJ; Kolev D; Aben KK; Bryan RT; Catto JWF; Cheng KK; Conroy S; Dyrskjøt L; Fleshner NE; James ND; Lamy P; Lindskrog SV; Malats N; Mengual L; Verhaegh G; Zeegers MP; Kiemeney LALM; Vermeulen SH
Eur Urol Oncol; 2022 Feb; 5(1):70-83. PubMed ID: 34353775
[TBL] [Abstract][Full Text] [Related]
35. Low-Dose Versus Standard Dose of Bacillus Calmette-Guerin in the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Zeng S; Yu X; Ma C; Zhang Z; Song R; Chen X; Sun Y; Xu C
Medicine (Baltimore); 2015 Dec; 94(49):e2176. PubMed ID: 26656345
[TBL] [Abstract][Full Text] [Related]
36. Enhanced Visualization Methods for First Transurethral Resection of Bladder Tumour in Suspected Non-muscle-invasive Bladder Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(12):1-123. PubMed ID: 34484486
[TBL] [Abstract][Full Text] [Related]
37. Dose, duration and strain of bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer: Meta-analysis of randomized clinical trials.
Quan Y; Jeong CW; Kwak C; Kim HH; Kim HS; Ku JH
Medicine (Baltimore); 2017 Oct; 96(42):e8300. PubMed ID: 29049231
[TBL] [Abstract][Full Text] [Related]
38. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
[TBL] [Abstract][Full Text] [Related]
39. Intravesical Therapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis of Disease Recurrence.
Laukhtina E; Abufaraj M; Al-Ani A; Ali MR; Mori K; Moschini M; Quhal F; Sari Motlagh R; Pradere B; Schuettfort VM; Mostafaei H; Katayama S; Grossmann NC; Fajkovic H; Soria F; Enikeev D; Shariat SF;
Eur Urol Focus; 2022 Mar; 8(2):447-456. PubMed ID: 33762203
[TBL] [Abstract][Full Text] [Related]
40. Can we offer additional BCG therapy for three-month BCG refractory high grade/T1, Tis bladder cancer patients?
Elsawy AA; Laymon M; Mansour I; Elghareeb A; Harraz A
Arab J Urol; 2023; 21(3):142-149. PubMed ID: 37521452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
